Skip to content
Peptide research

Thymosin Beta-4

Also known as TB4 · Tβ4
Category
Tissue Repair & Recovery
Administration routes
Injectable
Regulatory status
Not FDA-approved

A 43-amino-acid peptide, sold mostly as the synthetic fragment TB-500 and marketed for wound healing and tendon and muscle repair. The case rests almost entirely on animal and mechanism work, so the human benefit case is weak. It promotes blood-vessel growth and cell migration, leaving a theoretical tumor concern unresolved and long-term safety unestablished. Not an approved US drug; most supply consists of unregulated products sold online, of uncertain purity.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Thymosin Beta-4 (Tb4) is a naturally occurring 43-amino-acid peptide that is the most abundant member of the beta-thymosin family. Found in virtually all tissues and cell types (except red blood cells), it plays a central role in wound healing, tissue repair, and regeneration. Thymosin Beta-4 is distinct from TB-500, which is a smaller synthetic fragment corresponding to the active region (amino acids 17-23) of the full Tb4 protein. The full-length Thymosin Beta-4 molecule was originally isolated from the thymus gland in the 1960s and has since been shown to promote cell migration, angiogenesis, stem cell differentiation, and anti-inflammatory responses.

Thymosin Beta-4 works primarily by sequestering G-actin monomers, which regulates actin polymerization and is essential for cell motility and migration. After injury, Tb4 is released by platelets, macrophages, and other cell types to protect damaged cells and tissues from further harm. It reduces apoptosis and inflammation, promotes angiogenesis (new blood vessel formation), and stimulates the mobilization and differentiation of stem and progenitor cells. Notably, it also decreases the number of myofibroblasts in wounds, which reduces scar formation and fibrosis.

Clinical research on Thymosin Beta-4 has been extensive in preclinical models, with strong wound healing data in dermal, corneal, and cardiac injury models. RegeneRx Biopharmaceuticals developed the clinical-grade form (RGN-259) as an eye drop for neurotrophic keratopathy and dry eye, and topical formulations for chronic dermal wounds. Development has reached Phase 3, but dry-eye trials missed their prespecified coprimary endpoints and no formulation has received FDA approval. The peptide remains under investigation for regenerative uses across multiple organ systems.

How it works in the body

A 43-amino-acid peptide that sequesters G-actin monomers, regulating actin polymerization which is essential for cell migration and wound healing. It promotes angiogenesis, reduces inflammation via NF-kB pathway modulation, and activates resident stem/progenitor cells. TB-500 is a synthetic fragment; the full protein has broader biological activity.

Research overview

Thymosin Beta-4 has been studied in hundreds of preclinical models and a growing number of human clinical trials. The seminal 1999 study by Malinda et al. in the Journal of Investigative Dermatology demonstrated that topical or intraperitoneal Tb4 increased reepithelialization by 42-61% over controls in a rat full-thickness wound model, with increased collagen deposition and angiogenesis (PMID 10469335). A comprehensive 2012 review by Goldstein and Kleinman in Expert Opinion on Biological Therapy (PMID 22074294) summarized Tb4's multi-functional regenerative activities across skin, eye, heart, and brain. Clinical-stage development includes RegeneRx's RGN-259 eye drops for neurotrophic keratopathy (Phase 2/3), dry eye disease (Phase 3), and topical Tb4 for epidermolysis bullosa and chronic dermal wounds. Cardiac research has shown Tb4 can reduce infarct size, promote cardiomyocyte survival, and activate epicardial progenitor cells after myocardial ischemia in preclinical models. As of 2026, PubMed indexes over 1,200 publications mentioning thymosin beta-4, though the majority are preclinical. Human clinical trials remain limited.

Who researches Thymosin Beta-4?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

Important considerations for

  • Those with Active cancer

    High

    Promotes cell migration, angiogenesis, and tissue remodeling — same concerns as TB-500 (its active fragment).

  • Those who are pregnant or breastfeeding

    Absolute

    No reproductive safety data.

Safety & interactions

Do not use if

  • Active cancer

    High

    Promotes cell migration, angiogenesis, and tissue remodeling — same concerns as TB-500 (its active fragment).

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(3)

Rated by level of concern

  • Long-term human safety not established

    Moderate

    RGN-352 Phase 1 (80 subjects, well-tolerated); RGN-259 short-term Phase 2/3 ophthalmic trials

  • Promotes angiogenesis/cell migration; theoretical tumor concern

    Moderate

    Cha et al., role in tumor metastasis/angiogenesis PMID 14625258; colon cancer ILK/IQGAP1/Rac1 (Cancer Lett); hepatoblastoma EMT PMC4438935

  • Mild injection site reactions when given subcutaneously

    Low

    Ruff et al., 2010, PMID 20536472: intravenous thymosin beta-4 in healthy volunteers; this study does not establish subcutaneous injection-site effects.

Interaction summary(6)

Rated by direction with this peptide

  • Anti-angiogenic / anti-VEGF therapies (e.g., bevacizumab, aflibercept, ranibizumab)

    CautionTheoretical

    Tbeta4 promotes angiogenesis by stabilizing HIF-1alpha and inducing VEGF, so it could theoretically blunt the intended effect of anti-angiogenic agents; no clinical interaction data.

    Mechanism: HIF-1alpha/VEGF induction (Ock 2012); Grant angiogenesis review 2007

  • Cytotoxic chemotherapy / active malignancy

    CautionModerate

    Because multiple preclinical models show Tbeta4 enhances tumor-cell migration, EMT and metastasis, concurrent use during active cancer treatment is a mechanism-based caution rather than a proven human interaction.

    PMID 14625258; colon cancer metastasis ILK/IQGAP1/Rac1 (Cancer Lett 2011)

  • Systemic or topical corticosteroids

    ProtectiveTheoretical

    Corticosteroids impair re-epithelialization; Tbeta4's pro-migratory, pro-healing, NF-kB-suppressing activity could counteract steroid-impaired wound healing and complement anti-inflammatory effects — mechanistic, not clinically tested in combination.

    Mechanism: Tbeta4 reepithelialization (PMID 10469335) + NF-kB suppression (PMC2211446)

  • Pro-angiogenic / growth-factor wound agents (e.g., becaplermin/PDGF, VEGF)

    SynergisticTheoretical

    Overlapping angiogenic and cell-migration pathways suggest additive wound-healing benefit when combined, but this has not been tested in humans.

    Mechanism: shared angiogenesis/cell-migration pathways (Grant 2007)

  • Topical immunomodulators for ocular surface disease (cyclosporine, lifitegrast)

    SynergisticTheoretical

    In dry eye / ocular-surface disease, Tbeta4 (RGN-259) reduces NF-kB-driven inflammation and could complement immunomodulators; not formally studied as a combination.

    Mechanism: corneal NF-kB suppression (PMC2211446); RGN-259 dry-eye program

  • CYP450-metabolized drugs (general pharmacokinetic interactions)

    NeutralLow

    As a small 43-aa peptide cleared by proteolysis rather than hepatic CYP enzymes, Tbeta4 is not expected to cause classic CYP- or transporter-mediated drug-drug interactions.

    Peptide pharmacology (proteolytic clearance); no CYP interaction data reported

Known risks(3)

  • Limited long-term human safety data

    While Tb4 is naturally present in the body and preclinical toxicology is reassuring, long-term safety data from controlled human trials are limited. Most clinical data comes from short-duration Phase 2 ophthalmology studies.

  • Theoretical concern about promoting growth of existing tumors

    Theoretical

    Because Tb4 promotes angiogenesis and cell migration, there is a theoretical concern that it could support tumor vascularization or metastasis in individuals with existing cancers. Some studies have found elevated Tb4 levels in certain tumor types. However, no clinical evidence of tumor promotion has been observed in trials.

  • Injection site reactions (subcutaneous formulations)

    Mild

    The cited full-length thymosin beta-4 safety study used intravenous administration and does not establish the frequency or severity of injection-site reactions after subcutaneous use.

Drug interactions(3)

  • Anticoagulants (warfarin, heparin, DOACs)

    Tb4 promotes angiogenesis and wound healing; combined use with anticoagulants may alter bleeding dynamics at wound sites. No direct pharmacokinetic interaction established, but caution warranted.

  • Immunosuppressants (cyclosporine, tacrolimus, corticosteroids)

    Tb4 has anti-inflammatory and immunomodulatory properties. Co-administration with immunosuppressants may have additive effects on immune function. Clinical significance is not established.

  • Anti-angiogenic cancer therapies (bevacizumab, sunitinib)

    Tb4 promotes angiogenesis, which could theoretically counteract anti-angiogenic cancer drugs. Co-administration is not recommended in patients receiving anti-VEGF therapy.

Research & benefits

Evidence base

Evidence Level
Moderate Evidence (Strong Preclinical, Limited Human)
Total Studies
1200
Human Studies
200

Thymosin Beta-4 has exceptionally strong preclinical evidence across dermal, corneal, cardiac, and neurological injury models. Human clinical trials are more limited. RGN-259 reached Phase 3 trials in neurotrophic keratopathy and dry eye; encouraging secondary and subgroup findings have not established efficacy, and the dry-eye trials missed their prespecified coprimary endpoints. Topical Tb4 has been tested in small human wound healing studies showing accelerated healing. Cardiac applications remain in preclinical stages. The full 43-amino-acid protein has a substantially larger evidence base than the TB-500 fragment.

Researched for(6)

Rated by confidence in the evidence

  • Accelerated wound healing with increased reepithelialization (42-61% improvement)

    Low

    The 42-61% figure comes from a 1999 rat wound model; human skin trials missed their goals.

    Malinda et al., J Invest Dermatol 1999, PMID 10469335; human dermal trials: RegeneRx RGN-137 Phase 2 (pressure/venous ulcers) missed primary endpoints

  • Reduced scar formation and fibrosis through decreased myofibroblast activity

    Low

    Consistent animal and lab data show fewer scar-forming cells; no human anti-fibrosis trials yet.

    Corneal alpha-SMA reduction (IOVS/ARVO); cardiac fibroblast anti-fibrotic/anti-apoptotic data PMC3201979

  • Promoted corneal wound healing and reduced inflammation in eye injury models

    Medium

    Extensive animal data plus human eye trials, though pivotal trials showed only trends or missed goals.

    RGN-259 Phase 3 neurotrophic keratopathy PMC9820614; ARISE-2 dry eye (NCT02974907); SEER-3 missed primary endpoint (Ophthalmology Times)

  • Reduced cardiac infarct size and promoted cardiomyocyte survival in ischemic models

    Low

    A 2004 mouse study cut infarct size roughly in half; human testing reached only early safety.

    Bock-Marquette et al., Nature 2004, PMID 15565145; PMID 17600280; Frontiers Pharmacol 2013 (systemic dosing)

  • Anti-inflammatory effects and suppression of NF-kB-mediated cytokine release

    Low

    Well-characterized in cells and animal tissue via NF-kB; no dedicated human anti-inflammatory trial.

    Sosne et al., corneal NF-kB suppression PMC2211446; Tbeta4 inhibits TNF-alpha/NF-kB/IL-8 (PINCH-1/ILK) PMC3101037

  • Stimulated angiogenesis and new blood vessel formation in damaged tissue

    Low

    Robust, consistent lab and animal evidence for vessel growth; not yet measured in human trials.

    Grant et al. angiogenesis review, Angiogenesis 2007 (10.1007/s10456-007-9077-x); Malinda 1997 endothelial migration; HIF-1alpha/VEGF stabilization (Ock 2012)

Benefits(6)

  • Accelerated wound healing with increased reepithelialization (42-61% improvement)

    Malinda et al., J Invest Dermatol 1999 (PMID 10469335); Treadwell et al., Ann N Y Acad Sci 2012 (PMID 23050815)

  • Reduced scar formation and fibrosis through decreased myofibroblast activity

    Goldstein & Kleinman, Expert Opin Biol Ther 2012 (PMID 22074294)

  • Promoted corneal wound healing and reduced inflammation in eye injury models

    Sosne et al., Ann N Y Acad Sci 2007 (PMID 17804539); RGN-259 Phase 2 trials

  • Reduced cardiac infarct size and promoted cardiomyocyte survival in ischemic models

    Bock-Marquette et al., Nature 2004 (PMID 15565145); Smart et al., Nature 2007 (PMID 17581592)

  • Anti-inflammatory effects and suppression of NF-kB-mediated cytokine release

    Goldstein and Kleinman, Expert Opin Biol Ther 2015 (PMID 26096726)

  • Stimulated angiogenesis and new blood vessel formation in damaged tissue

    Malinda et al. 1999; Philp et al., Ann N Y Acad Sci 2010 (PMID 20536453)

Key studies(4)

  1. Thymosin beta4 accelerates wound healing

    Preclinical (in vivo rat model)n=multiple groups7 days

    Malinda KM, Kleinman HK, Sidhu GS, et al.

    Journal of Investigative Dermatology

    1999

    Topical or intraperitoneal Tb4 increased reepithelialization by 42% at day 4 and 61% at day 7 in a rat full-thickness wound model. Wounds contracted 11% more than controls. Increased collagen deposition and angiogenesis observed. Tb4 stimulated keratinocyte migration 2-3 fold at doses as low as 10 pg.

  2. Goldstein AL, Kleinman HK

    Expert Opinion on Biological Therapy

    2012

    Comprehensive review of Tb4 biology and clinical potential. Tb4 released by platelets and macrophages after injury protects cells, reduces apoptosis and inflammation, promotes angiogenesis, mobilizes stem/progenitor cells, and decreases scar formation. Clinical applications span skin, eye, heart, and CNS.

  3. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D

    Nature

    2004

    Tb4 promoted survival of cardiomyocytes after ischemic injury via activation of integrin-linked kinase (ILK) and Akt phosphorylation. Systemic Tb4 administration reduced infarct size in mice following coronary artery ligation.

  4. Treadwell T, Kleinman HK, Crockford D, Hardy MA, Guarnera GT, Goldstein AL

    Annals of the New York Academy of Sciences

    2012

    Tb4 accelerated dermal healing in multiple preclinical models and in a small number of human patients with chronic wounds. Evidence of improved reepithelialization, collagen deposition, and wound closure rates.

Regulation & availability

Why researchers look at it

Thymosin Beta-4 is one of the most extensively studied regenerative peptides in biology, with compelling evidence for accelerating wound healing, reducing scarring, and promoting tissue repair across skin, eye, heart, and brain. Its natural role as a master regulator of cell migration and tissue regeneration makes it a leading candidate for next-generation wound care and regenerative medicine.

FDA status
Thymosin Beta-4 is an investigational drug. It is not FDA-approved, and in the US it is available only through clinical trials; it is not eligible for compounding. RGN-259 eye drops have reached Phase 3 trials for neurotrophic keratopathy and dry eye disease. Full-length thymosin beta-4 is not covered by the draft interim compounding policy HHS posted on October 28, 2026, which names only the TB-500 fragment.
WADA status
Prohibited — WADA S2 (Peptide Hormones, Growth Factors). Thymosin Beta-4 and its fragment TB-500 are prohibited at all times (in- and out-of-competition) under the WADA Prohibited List as growth factors with regenerative properties. Multiple athletes have received anti-doping sanctions for TB-500 / Tb4 use, including in Australian Rules Football and other professional sports.
Prescribability
No — Investigational; not FDA-approved for any indication
Availability
Thymosin Beta-4 is not FDA-approved and is not available as a prescription drug. RegeneRx Biopharmaceuticals has developed clinical-grade formulations (RGN-259 eye drops, topical gel) that are available only through clinical trials.

International status

  • EU

    Not approved

  • US

    Not approved

  • Worldwide

    WADA prohibited (S2 peptide hormones)

Regulatory timeline(8)

  1. 1966
    Thymosin fraction 5 (containing Tb4) first isolated from thymus by Allan Goldstein
  2. 1981
    Thymosin Beta-4 sequenced and characterized as a 43-amino-acid peptide
  3. 1999
    Malinda et al. publish landmark wound healing study in J Invest Dermatol (PMID 10469335)
  4. 2004
    Bock-Marquette et al. publish cardiac repair data in Nature (PMID 15565145)
  5. 2010
    RegeneRx Biopharmaceuticals begins Phase 2 trials for RGN-259 in dry eye
  6. 2013-12-31
    FDA grants Orphan Drug Designation for RGN-259 for neurotrophic keratopathy
  7. 2018-2023
    Phase 2/3 clinical trials for RGN-259 in neurotrophic keratopathy ongoing
  8. 2026
    Thymosin Beta-4 remains investigational; no FDA approval for any indication

Sources & FAQs

Research sources(6)

Frequently asked questions(4)

What is the difference between Thymosin Beta-4 and TB-500?

Thymosin Beta-4 is the full-length, naturally occurring 43-amino-acid protein. TB-500 is a shorter synthetic fragment corresponding to the active region (amino acids 17-23) of Tb4. Both share core wound-healing activity, but the full protein has additional biological functions related to actin sequestration and cell motility.

What conditions is Thymosin Beta-4 being studied for?

Tb4 is being investigated for corneal wound healing (neurotrophic keratopathy, dry eye), chronic dermal wounds, cardiac repair after heart attack, neurological recovery after stroke or traumatic brain injury, and epidermolysis bullosa. The most advanced clinical programs are in ophthalmology.

Is Thymosin Beta-4 safe?

In clinical trials, Thymosin Beta-4 (as RGN-259 eye drops) has been well tolerated with no serious adverse events attributed to the drug. Preclinical toxicology studies show a wide safety margin. As a naturally occurring protein present in high concentrations throughout the body, it has a favorable safety profile, though long-term human safety data are still limited.

Can Thymosin Beta-4 help with heart repair?

Preclinical studies in mice and pigs have shown that Tb4 can reduce cardiac infarct size, promote cardiomyocyte survival, and activate epicardial progenitor cells. These findings were published in Nature (2004, 2007). However, no human cardiac trials have been completed, so this application remains experimental.